Cliff Asness’s Stoke Therapeutics STOK Stock Holding History

Cliff Asness’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$865K	Sell	26,449 -20,010	-43%	-$642K	﹤0.01%	3087
2026 Q1	$1.51M	Buy	46,459 +16,992	+58%	+$557K	﹤0.01%	2538
2025 Q4	$935K	Buy	29,467 +354	+1%	+$10.6K	﹤0.01%	2597
2025 Q3	$684K	Sell	29,113 -25,705	-47%	-$440K	﹤0.01%	2651
2025 Q2	$622K	Buy	54,818 +41,971	+327%	+$399K	﹤0.01%	2484
2025 Q1	$85.4K	Sell	12,847 -10,772	-46%	-$100K	﹤0.01%	3036
2024 Q4	$261K	Sell	23,619 -51,470	-69%	-$632K	﹤0.01%	2565
2024 Q3	$923K	Buy	+75,089	New	+$1.06M	﹤0.01%	1889

Other funds holding STOK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Cliff Asness's STOK Position: Q2 2026 in Review

Cliff Asness reduced its Stoke Therapeutics (STOK) stake by 43% in Q2 2026, selling an estimated $642K and leaving 26,449 shares worth $865K. The position accounts for ﹤0.01% of the portfolio, ranked #3087.

Cliff Asness first reported a position in STOK in Q3 2024 and has held it in 8 quarters since. The position peaked at $1.51M in Q1 2026. 196 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

Cliff Asness held 26,449 shares of Stoke Therapeutics worth $865K as of Q2 2026.
Cliff Asness sold 20,010 Stoke Therapeutics shares in Q2 2026, an estimated $642K.
Stoke Therapeutics made up ﹤0.01% of Cliff Asness's portfolio in Q2 2026, its #3087 holding.
Cliff Asness first reported a position in Stoke Therapeutics in Q3 2024 and has held it in 8 quarters since.
Cliff Asness's Stoke Therapeutics position peaked at $1.51M in Q1 2026.
196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.